ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood.
We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state.
Keep up to date with the latest ZS Pharma News and Updates
ZS Pharma Announces Publication of Results from Phase 3 Study of ZS-9 in Patients with Hyperkalemia in the New England Journal of MedicineDownload PDF
ZS Pharma Presents Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMADownload PDF
ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program UpdateDownload PDF